NO20014724L - Pregelatinisert stivelse i en formulering med regulert frigivning - Google Patents

Pregelatinisert stivelse i en formulering med regulert frigivning

Info

Publication number
NO20014724L
NO20014724L NO20014724A NO20014724A NO20014724L NO 20014724 L NO20014724 L NO 20014724L NO 20014724 A NO20014724 A NO 20014724A NO 20014724 A NO20014724 A NO 20014724A NO 20014724 L NO20014724 L NO 20014724L
Authority
NO
Norway
Prior art keywords
controlled release
release formulation
hydrophilic
pregelatinized starch
hydrophilic polymers
Prior art date
Application number
NO20014724A
Other languages
English (en)
Other versions
NO20014724D0 (no
NO332167B1 (no
Inventor
Roger Petrus Gerebe Vandecruys
Eugene Marie Jozef Jans
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20014724(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20014724D0 publication Critical patent/NO20014724D0/no
Publication of NO20014724L publication Critical patent/NO20014724L/no
Publication of NO332167B1 publication Critical patent/NO332167B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO20014724A 1999-03-31 2001-09-28 Pregelatinisert stivelse i en formulering med regulert frigivning NO332167B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201018 1999-03-31
PCT/EP2000/002620 WO2000059477A1 (en) 1999-03-31 2000-03-24 Pregelatinized starch in a controlled release formulation

Publications (3)

Publication Number Publication Date
NO20014724D0 NO20014724D0 (no) 2001-09-28
NO20014724L true NO20014724L (no) 2001-09-28
NO332167B1 NO332167B1 (no) 2012-07-09

Family

ID=8240051

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20014724A NO332167B1 (no) 1999-03-31 2001-09-28 Pregelatinisert stivelse i en formulering med regulert frigivning
NO20111249A NO342239B1 (no) 1999-03-31 2011-09-14 Pregelatinisert stivelse i en formulering med regulert frigiving

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20111249A NO342239B1 (no) 1999-03-31 2011-09-14 Pregelatinisert stivelse i en formulering med regulert frigiving

Country Status (27)

Country Link
US (3) US6667060B1 (no)
EP (3) EP1611881A1 (no)
JP (2) JP4928668B2 (no)
KR (3) KR20060097068A (no)
CN (1) CN1208090C (no)
AT (1) ATE313319T1 (no)
AU (1) AU776645B2 (no)
BG (3) BG65470B1 (no)
BR (1) BR0009437A (no)
CA (1) CA2371940C (no)
CZ (2) CZ2006443A3 (no)
DE (1) DE60024981T2 (no)
DK (1) DK1169024T3 (no)
EA (2) EA005291B1 (no)
EE (1) EE05022B1 (no)
ES (2) ES2255490T3 (no)
HK (1) HK1044715B (no)
HR (1) HRP20010700B1 (no)
HU (1) HU230440B1 (no)
IL (3) IL145661A0 (no)
MX (1) MX339071B (no)
NO (2) NO332167B1 (no)
NZ (1) NZ514890A (no)
PL (1) PL198797B1 (no)
SI (1) SI1169024T1 (no)
SK (1) SK288541B6 (no)
WO (1) WO2000059477A1 (no)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2371940C (en) * 1999-03-31 2008-07-15 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
CA2428971A1 (en) * 2000-11-14 2003-05-01 New River Pharmaceuticals Inc. Conjugates of a therapeutic agent and a peptide carrier
US20110092677A1 (en) * 2001-08-30 2011-04-21 Biorexis Technology, Inc. Modified transferin-antibody fusion proteins
US7357891B2 (en) * 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20060039958A1 (en) * 2003-05-28 2006-02-23 Monosolrx, Llc. Multi-layer films having uniform content
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8663687B2 (en) * 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US7425292B2 (en) * 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
PT1443917E (pt) * 2001-11-07 2006-06-30 Synthon Bv Comprimidos de tamsulosina
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
WO2003103634A1 (en) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Sustained release oral dosage forms of gabapentin
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20050079217A1 (en) * 2002-07-25 2005-04-14 Ganorkar Loksidh D. Sustained-release tablet composition comprising a dopamine receptor agonist
MY142204A (en) * 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
AU2007254665B2 (en) * 2002-07-29 2010-08-19 Alza Corporation Methods and dosage forms for controlled delivery and paliperidone
KR100699516B1 (ko) * 2002-07-29 2007-03-26 알자 코포레이션 팔리페리돈의 조절 전달을 위한 방법 및 복용 형태
EP1556019A2 (en) * 2002-10-24 2005-07-27 Merz Pharma GmbH & Co. KGaA Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2004058152A2 (en) * 2002-12-16 2004-07-15 Ranbaxy Pharmaceuticals Inc. An extended release pharmaceutical composition of phenytoin sodium
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
PL1638529T3 (pl) 2003-06-16 2017-03-31 Andrx Pharmaceuticals, Llc. Kompozycja doustna o przedłużonym uwalnianiu
US9101155B2 (en) 2003-07-11 2015-08-11 Asahi Kasei Chemicals Corporation Functional starch powder
TWI366442B (en) * 2003-07-30 2012-06-21 Novartis Ag Palatable ductile chewable veterinary composition
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
WO2005087198A1 (en) * 2004-03-10 2005-09-22 Ranbaxy Laboratories Limited Processes for the preparation of solid dosage forms of amorphous valganciclovir hydrochloride
WO2005067887A2 (en) 2004-03-24 2005-07-28 Actavis Group Formulations of ramipril
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
EP1591107A1 (en) * 2004-04-28 2005-11-02 Pfizer GmbH Arzneimittelwerk Gödecke Process for the selective increase of a release rate of an active material from a pharmaceutical composition
BRPI0510453A (pt) 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
TWI338583B (en) 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
CA2576386A1 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
PL1789021T3 (pl) * 2004-08-13 2012-04-30 Boehringer Ingelheim Int Preparat tabletkowy o przedłużonym uwalnianiu zawierający pramipeksol lub jego farmaceutycznie dopuszczalną sól
WO2006028362A1 (es) * 2004-09-09 2006-03-16 Psicofarma, S.A. De C.V. Composición farmacéutica de liberación prolongada de hidralazina y su uso como apoyo para el tratamiento del cáncer
CA2586547A1 (en) * 2004-11-05 2006-05-11 King Pharmaceuticals Research & Development, Inc. Stabilized individually coated ramipril particles, compositions and methods
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
US20060105992A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
US20060121108A1 (en) * 2004-12-02 2006-06-08 Prasad C K System and method for producing a directly compressible, high-potency formulation of metformin hydrochloride
AU2005320547B2 (en) 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
ZA200707250B (en) * 2005-01-27 2009-06-24 Alembic Ltd Extended release formulation of levetiracetam
AU2006241771B2 (en) * 2005-04-28 2010-09-09 Eisai R & D Management Co., Ltd. Composition containing anti-dementia drug
DK2444079T3 (en) * 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
AU2006250340C1 (en) * 2005-05-26 2014-06-12 Sumitomo Pharma Co., Ltd. Pharmaceutical composition
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8252776B2 (en) * 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
DE102005033943A1 (de) * 2005-07-20 2007-02-22 Hexal Ag Nicht-ausspuckbarer, oraler, schnell-zerfallender Film für ein Neuroleptikum
US20100209503A1 (en) * 2005-08-10 2010-08-19 Yoichi Taniguchi Bitter Taste Masking Dosage Form
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
US7803413B2 (en) * 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
DE102006003512A1 (de) * 2006-01-24 2007-08-02 Bayer Schering Pharma Ag Plättchenförmige Arzneimittel zur transbukkalen Applikation von Arzneistoffen
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
US20070264346A1 (en) * 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
KR101181194B1 (ko) 2006-10-18 2012-09-18 화이자 프로덕츠 인코포레이티드 바이아릴 에터 우레아 화합물
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
RU2438352C2 (ru) * 2007-05-23 2012-01-10 Фирмениш Са Вкусоароматическая композиция
US20080292683A1 (en) * 2007-05-24 2008-11-27 Monosolrx, Llc. Film shreds and delivery system incorporating same
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2155170A2 (en) * 2007-06-08 2010-02-24 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
MX2009007764A (es) * 2007-06-08 2009-09-10 Boehringer Ingelheim Pharma Formulacion de nevirapina de liberacion prolongada.
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
US9078824B2 (en) 2007-09-24 2015-07-14 The Procter & Gamble Company Composition and method of stabilized sensitive ingredient
US20090081294A1 (en) * 2007-09-26 2009-03-26 Gin Jerry B Sustained release dosage form for lubricating an oral cavity
US20090081291A1 (en) * 2007-09-26 2009-03-26 Gin Jerry B Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User
ES2541809T3 (es) * 2007-10-16 2015-07-24 Paladin Labs Inc. Composición bicapa para la liberación sostenida de acetaminofeno y tramadol
US8298583B2 (en) 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
US20090155176A1 (en) 2007-10-19 2009-06-18 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
EP2219612A4 (en) 2007-12-17 2013-10-30 Paladin Labs Inc CONTROLLED RELEASE FORMULATION AVOIDING IMPROPER USES
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
EP2262484B1 (en) 2008-03-11 2013-01-23 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
EP2276508A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc RELEASE OF LFA-1 ANTAGONISTS AGAINST THE GAS-DARM SYSTEM
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2013205004B2 (en) * 2008-06-30 2015-08-27 Tocagen Inc. Formulations of 5-fluorocytosine and Uses Thereof
CA2724740C (en) * 2008-06-30 2017-02-21 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CN102118970A (zh) 2008-07-16 2011-07-06 吉瑞工厂 包含多巴胺受体配体的药物制剂
MX2011000825A (es) * 2008-07-22 2011-02-25 Gen Mills Inc Productos frutales que contienen acidos grasos omega-3.
WO2010017310A1 (en) 2008-08-06 2010-02-11 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US20100040727A1 (en) * 2008-08-18 2010-02-18 Monosol Rx, Llc Method for Improving Uniformity of Content in Edible Film Manufacturing
JP2012508713A (ja) * 2008-11-17 2012-04-12 ビーエーエスエフ ソシエタス・ヨーロピア デンプン含有顆粒製剤
US8282954B2 (en) * 2008-12-15 2012-10-09 Monosol Rx, Llc Method for manufacturing edible film
EP2367541B1 (en) 2008-12-16 2014-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
EA026651B1 (ru) 2009-01-23 2017-05-31 Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. Фармацевтический или пищевой состав с контролируемым высвобождением и способ его получения
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
US20100285130A1 (en) * 2009-05-06 2010-11-11 Monosol Rx, Llc Coating of complexed actives in film formulations
US20100297232A1 (en) * 2009-05-19 2010-11-25 Monosol Rx, Llc Ondansetron film compositions
IN2012DN00311A (no) 2009-07-09 2015-05-08 Oshadi Drug Administration Ltd
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US8378105B2 (en) * 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US20110142942A1 (en) * 2009-12-10 2011-06-16 Monosol Rx, Llc USE OF pH SENSITIVE COMPOUNDS IN TASTE MASKING OF DRUG SUBSTANCES WITHIN ORAL THIN FILM STRIPS
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
AU2010343147A1 (en) * 2009-12-28 2012-07-19 Monosol Rx, Llc Orally administrable film dosage forms containing ondansetron
CN104224737A (zh) * 2010-02-24 2014-12-24 硕腾有限责任公司 兽医组合物
US8975387B1 (en) 2010-03-22 2015-03-10 North Carolina State University Modified carbohydrate-chitosan compounds, methods of making the same and methods of using the same
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
WO2012084759A2 (en) * 2010-12-21 2012-06-28 Akzo Nobel Chemicals International B.V. Instant powders for aqueous cosmetic applications
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
JP5960523B2 (ja) * 2012-06-29 2016-08-02 旭化成株式会社 加工澱粉と溶出制御剤からなる固形製剤
KR102157608B1 (ko) 2012-07-25 2020-09-18 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체
WO2014017573A1 (ja) * 2012-07-27 2014-01-30 大正製薬株式会社 外用剤組成物
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US20160220630A1 (en) 2013-10-10 2016-08-04 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
US9561187B1 (en) * 2014-02-03 2017-02-07 CMAX Technologies, Inc. Sustained release metoprolol formulations
WO2015148415A2 (en) * 2014-03-26 2015-10-01 Canget Biotekpharma, Llc Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease
CN103948550A (zh) * 2014-04-22 2014-07-30 青岛市市立医院 一种西沙必利分散片及其制备方法
KR20170016386A (ko) 2014-06-02 2017-02-13 테티스, 아이엔씨. 개질된 생체중합체, 및 이의 제조 및 사용 방법
BE1021194B1 (nl) * 2014-07-07 2015-07-14 Nordic Specialty Pharma Bvba Paracetamol tabletten
EP3380577A4 (en) 2015-11-23 2019-04-17 Tethis, Inc. COATED PARTICLES AND METHODS OF PRODUCTION AND USE
US10653744B2 (en) 2016-01-11 2020-05-19 Bausch Health Ireland Limited Formulations and methods for treating ulcerative colitis
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
JP2019519487A (ja) 2016-05-05 2019-07-11 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
CN107198680A (zh) * 2016-10-12 2017-09-26 钟术光 缓释制剂
JP7426685B2 (ja) * 2018-06-14 2024-02-02 株式会社東洋新薬 錠剤
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
GB2606585B (en) * 2021-03-31 2024-02-14 Tate & Lyle Solutions Usa Llc Pregelatinized inhibited hollow starch products and methods of making and using them

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
JPS615027A (ja) * 1984-06-18 1986-01-10 Sadahiro Nakano 徐放性固形製剤
GB8624213D0 (en) * 1986-10-09 1986-11-12 Sandoz Canada Inc Sustained release pharmaceutical compositions
FR2610827B1 (fr) * 1987-02-18 1991-09-13 Pf Medicament Comprime de dihydroergotamine (d.h.e.) du type a matrice hydrophile et son procede de fabrication
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US4806359A (en) * 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
FR2666506A1 (fr) * 1990-09-07 1992-03-13 Pf Medicament Comprime a liberation prolongee a base de 5-mononitrate d'isosorbide et son procede de preparation.
US5534496A (en) * 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
DE69427466T2 (de) * 1993-02-26 2002-04-25 The Procter & Gamble Company, Cincinnati Bisacodyl dosierungsform
US5698226A (en) 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
US5635208A (en) * 1993-07-20 1997-06-03 Mcneil-Ppc, Inc. Granulation process for producing an acetaminophen and diphenhydramine hydrochloride composition and composition produced by same
TW349870B (en) 1993-09-30 1999-01-11 Janssen Pharmaceutica Nv An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof
JPH07204796A (ja) * 1994-01-14 1995-08-08 Kawasaki Steel Corp 金属薄帯の製造装置
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release
EP0826376B1 (en) * 1995-05-02 2007-01-24 Taisho Pharmaceutical Co. Ltd Composition for oral administration
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
JPH0952832A (ja) * 1995-08-10 1997-02-25 Takeda Chem Ind Ltd 医薬組成物
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
EA000818B1 (ru) * 1995-12-27 2000-04-24 Жансен Фармасетика Н.В. Биоадгезивная твердая дозированная лекарственная форма
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
PL193563B1 (pl) * 1998-09-26 2007-02-28 Sanofi Aventis Deutschland Sposób wytwarzania kwasu alfa, alfa-dimetylofenylooctowego
CA2371940C (en) * 1999-03-31 2008-07-15 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation

Also Published As

Publication number Publication date
IL145661A (en) 2013-10-31
KR20020002384A (ko) 2002-01-09
KR100660594B1 (ko) 2006-12-22
EP1169024B1 (en) 2005-12-21
IL145661A0 (en) 2002-06-30
CN1208090C (zh) 2005-06-29
CA2371940A1 (en) 2000-10-12
SK288541B6 (sk) 2018-03-05
HK1044715B (zh) 2006-02-17
HU230440B1 (hu) 2016-06-28
EP1649851A2 (en) 2006-04-26
NO20014724D0 (no) 2001-09-28
EE200100505A (et) 2002-12-16
CZ20013375A3 (cs) 2002-05-15
AU3963800A (en) 2000-10-23
JP2002541090A (ja) 2002-12-03
SI1169024T1 (sl) 2006-06-30
CA2371940C (en) 2008-07-15
KR20060097068A (ko) 2006-09-13
PL355096A1 (en) 2004-03-22
NZ514890A (en) 2003-05-30
EP1649851B1 (en) 2018-06-20
US20090191266A1 (en) 2009-07-30
ATE313319T1 (de) 2006-01-15
AU776645B2 (en) 2004-09-16
CN1345233A (zh) 2002-04-17
HK1044715A1 (en) 2002-11-01
JP2011006485A (ja) 2011-01-13
EA200401009A1 (ru) 2004-12-30
HRP20010700B1 (en) 2011-01-31
CZ307700B6 (cs) 2019-02-20
SK13542001A3 (sk) 2002-08-06
EP1169024A1 (en) 2002-01-09
US8591945B2 (en) 2013-11-26
EA200101026A1 (ru) 2002-06-27
PL198797B1 (pl) 2008-07-31
HUP0200611A2 (hu) 2002-07-29
ES2255490T3 (es) 2006-07-01
ES2688273T3 (es) 2018-10-31
DE60024981T2 (de) 2006-09-14
BG110060A (bg) 2008-12-30
IL219820A0 (en) 2012-06-28
MX339071B (es) 2016-05-09
JP4928668B2 (ja) 2012-05-09
BG105857A (en) 2002-04-30
WO2000059477A1 (en) 2000-10-12
DK1169024T3 (da) 2006-05-08
BG66095B1 (bg) 2011-04-29
CZ2006443A3 (cs) 2019-02-20
EP1649851A3 (en) 2008-04-23
EA005291B1 (ru) 2004-12-30
HRP20010700A2 (en) 2003-04-30
EP1611881A1 (en) 2006-01-04
EE05022B1 (et) 2008-06-16
US6667060B1 (en) 2003-12-23
MXPA01009877A (es) 2002-05-06
NO20111249L (no) 2001-09-28
CZ300551B6 (cs) 2009-06-17
DE60024981D1 (de) 2006-01-26
HUP0200611A3 (en) 2003-04-28
BR0009437A (pt) 2002-01-15
US20040062805A1 (en) 2004-04-01
BG65470B1 (bg) 2008-09-30
NO342239B1 (no) 2018-04-23
KR20100036398A (ko) 2010-04-07
NO332167B1 (no) 2012-07-09

Similar Documents

Publication Publication Date Title
DK1169024T3 (da) Prægelatineret stivelse i en formulering med kontrolleret frigivelse
EP0966966A3 (en) Nefazodone dosage form
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
IL131651A0 (en) A pharmaceutical formulation containing benzimidazoles with amino acid/caclodextrin combinations and a process for producing the same
CA2385890A1 (en) Controlled release compositions comprising nimesulide
WO2000041681A3 (de) ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN
ES2157881T3 (es) Metanosulfonato de paroxetina.
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
BG108516A (en) Pharmaceutical formulation
AU2003238221A1 (en) Ibuprofen suspension
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
WO2002011694A3 (en) COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS
ES2130081B1 (es) Comprimido de maleato de trimebutina con recubrimiento laminar.
SE0001916D0 (sv) Novel formulation
MY145885A (en) Controlled release formulations for oral administration

Legal Events

Date Code Title Description
MK1K Patent expired